Definition for Code SystemProteinModificationTypeExample

@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

<http://hl7.org/fhir/CodeSystem/protein-modification-type> a fhir:CodeSystem ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "protein-modification-type"] ; # 
  fhir:meta [
     fhir:lastUpdated [ fhir:v "2026-07-04T18:53:58.933+00:00"^^xsd:dateTime ]
  ] ; # 
  fhir:text [
     fhir:status [ fhir:v "generated" ] ;
     fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem protein-modification-type</b></p><a name=\"protein-modification-type\"> </a><a name=\"hcprotein-modification-type\"> </a><p>This case-sensitive code system <code>http://hl7.org/fhir/protein-modification-type</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">PEGylated<a name=\"protein-modification-type-PEGylated\"> </a></td><td>PEGylated</td><td>Conjugated to one or more polyethylene glycol (PEG) chains for half-life extension. Examples: pegfilgrastim, peginterferon, certolizumab pegol.</td></tr><tr><td style=\"white-space:nowrap\">lipidated<a name=\"protein-modification-type-lipidated\"> </a></td><td>Lipidated</td><td>Conjugated to a fatty acid chain (acylation) for half-life extension via albumin binding. Examples: semaglutide, liraglutide, insulin detemir, insulin degludec.</td></tr><tr><td style=\"white-space:nowrap\">Fc-fused<a name=\"protein-modification-type-Fc-fused\"> </a></td><td>Fc fusion</td><td>Fused to an immunoglobulin Fc region for half-life extension and effector function. Examples: etanercept, abatacept, aflibercept, dulaglutide.</td></tr><tr><td style=\"white-space:nowrap\">albumin-fused<a name=\"protein-modification-type-albumin-fused\"> </a></td><td>Albumin fusion</td><td>Fused to human serum albumin for half-life extension. Example: albiglutide.</td></tr><tr><td style=\"white-space:nowrap\">drug-conjugated<a name=\"protein-modification-type-drug-conjugated\"> </a></td><td>Drug-conjugated (ADC)</td><td>Conjugated to a small-molecule drug payload via a linker (antibody-drug conjugate). Examples: trastuzumab emtansine, brentuximab vedotin, gemtuzumab ozogamicin.</td></tr><tr><td style=\"white-space:nowrap\">polysaccharide-conjugated<a name=\"protein-modification-type-polysaccharide-conjugated\"> </a></td><td>Polysaccharide-conjugated</td><td>Conjugated to a polysaccharide antigen for vaccine immunogenicity. Examples: Hib, pneumococcal and meningococcal conjugate vaccines.</td></tr><tr><td style=\"white-space:nowrap\">glycoengineered<a name=\"protein-modification-type-glycoengineered\"> </a></td><td>Glycoengineered</td><td>Glycan structure engineered (e.g. afucosylated) to alter biological activity. Examples: obinutuzumab, mogamulizumab (enhanced ADCC).</td></tr><tr><td style=\"white-space:nowrap\">amino-acid-substituted<a name=\"protein-modification-type-amino-acid-substituted\"> </a></td><td>Amino acid substituted</td><td>Sequence carries one or more amino acid substitutions relative to a natural or parent protein. Examples: insulin analogs lispro, aspart, glargine.</td></tr><tr><td style=\"white-space:nowrap\">truncated<a name=\"protein-modification-type-truncated\"> </a></td><td>Truncated</td><td>Sequence is shortened relative to the parent protein.</td></tr><tr><td style=\"white-space:nowrap\">biotinylated<a name=\"protein-modification-type-biotinylated\"> </a></td><td>Biotinylated</td><td>Covalently labelled with biotin. Typical for research or diagnostic reagents.</td></tr><tr><td style=\"white-space:nowrap\">fluorescent-labeled<a name=\"protein-modification-type-fluorescent-labeled\"> </a></td><td>Fluorescent labelled</td><td>Covalently labelled with a fluorescent dye. Typical for imaging or flow-cytometry reagents.</td></tr></table></div>"^^rdf:XMLLiteral ]
  ] ; # 
  fhir:extension ( [
     fhir:url [
       fhir:v "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg"^^xsd:anyURI ;
       fhir:l <http://hl7.org/fhir/StructureDefinition/structuredefinition-wg>
     ] ;
     fhir:value [
       a fhir:Code ;
       fhir:v "brr"
     ]
  ] [
     fhir:url [
       fhir:v "http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status"^^xsd:anyURI ;
       fhir:l <http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status>
     ] ;
     fhir:value [
       a fhir:Code ;
       fhir:v "informative"
     ]
  ] [
     fhir:url [
       fhir:v "http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm"^^xsd:anyURI ;
       fhir:l <http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm>
     ] ;
     fhir:value [
       a fhir:Integer ;
       fhir:v 1
     ]
  ] ) ; # 
  fhir:url [
     fhir:v "http://hl7.org/fhir/protein-modification-type"^^xsd:anyURI ;
     fhir:l <http://hl7.org/fhir/protein-modification-type>
  ] ; # 
  fhir:version [ fhir:v "6.0.0-ballot4"] ; # 
  fhir:name [ fhir:v "ProteinModificationTypeExample"] ; # 
  fhir:title [ fhir:v "Protein Modification Type"] ; # 
  fhir:status [ fhir:v "active"] ; # 
  fhir:experimental [ fhir:v true] ; # 
  fhir:date [ fhir:v "2026-06-30"^^xsd:date] ; # 
  fhir:publisher [ fhir:v "HL7 (FHIR Project)"] ; # 
  fhir:contact ( [
     fhir:telecom ( [
       fhir:system [ fhir:v "url" ] ;
       fhir:value [ fhir:v "http://hl7.org/fhir" ]
     ] [
       fhir:system [ fhir:v "email" ] ;
       fhir:value [ fhir:v "fhir@lists.hl7.org" ]
     ] )
  ] ) ; # 
  fhir:description [ fhir:v "A high-level summary of how a protein has been modified, e.g. PEGylation, lipidation, Fc fusion. Useful for categorising modified biologics without enumerating the detailed chemistry."] ; # 
  fhir:jurisdiction ( [
     fhir:coding ( [
       fhir:system [
         fhir:v "http://unstats.un.org/unsd/methods/m49/m49.htm"^^xsd:anyURI ;
         fhir:l <http://unstats.un.org/unsd/methods/m49/m49.htm>
       ] ;
       fhir:code [ fhir:v "001" ] ;
       fhir:display [ fhir:v "World" ]
     ] )
  ] ) ; # 
  fhir:caseSensitive [ fhir:v true] ; # 
  fhir:valueSet [
     fhir:v "http://hl7.org/fhir/ValueSet/protein-modification-type"^^xsd:anyURI ;
     fhir:l <http://hl7.org/fhir/ValueSet/protein-modification-type>
  ] ; # 
  fhir:hierarchyMeaning [] ; # 
  fhir:content [ fhir:v "complete"] ; # 
  fhir:concept ( [
     fhir:code [ fhir:v "PEGylated" ] ;
     fhir:display [ fhir:v "PEGylated" ] ;
     fhir:definition [ fhir:v "Conjugated to one or more polyethylene glycol (PEG) chains for half-life extension. Examples: pegfilgrastim, peginterferon, certolizumab pegol." ]
  ] [
     fhir:code [ fhir:v "lipidated" ] ;
     fhir:display [ fhir:v "Lipidated" ] ;
     fhir:definition [ fhir:v "Conjugated to a fatty acid chain (acylation) for half-life extension via albumin binding. Examples: semaglutide, liraglutide, insulin detemir, insulin degludec." ]
  ] [
     fhir:code [ fhir:v "Fc-fused" ] ;
     fhir:display [ fhir:v "Fc fusion" ] ;
     fhir:definition [ fhir:v "Fused to an immunoglobulin Fc region for half-life extension and effector function. Examples: etanercept, abatacept, aflibercept, dulaglutide." ]
  ] [
     fhir:code [ fhir:v "albumin-fused" ] ;
     fhir:display [ fhir:v "Albumin fusion" ] ;
     fhir:definition [ fhir:v "Fused to human serum albumin for half-life extension. Example: albiglutide." ]
  ] [
     fhir:code [ fhir:v "drug-conjugated" ] ;
     fhir:display [ fhir:v "Drug-conjugated (ADC)" ] ;
     fhir:definition [ fhir:v "Conjugated to a small-molecule drug payload via a linker (antibody-drug conjugate). Examples: trastuzumab emtansine, brentuximab vedotin, gemtuzumab ozogamicin." ]
  ] [
     fhir:code [ fhir:v "polysaccharide-conjugated" ] ;
     fhir:display [ fhir:v "Polysaccharide-conjugated" ] ;
     fhir:definition [ fhir:v "Conjugated to a polysaccharide antigen for vaccine immunogenicity. Examples: Hib, pneumococcal and meningococcal conjugate vaccines." ]
  ] [
     fhir:code [ fhir:v "glycoengineered" ] ;
     fhir:display [ fhir:v "Glycoengineered" ] ;
     fhir:definition [ fhir:v "Glycan structure engineered (e.g. afucosylated) to alter biological activity. Examples: obinutuzumab, mogamulizumab (enhanced ADCC)." ]
  ] [
     fhir:code [ fhir:v "amino-acid-substituted" ] ;
     fhir:display [ fhir:v "Amino acid substituted" ] ;
     fhir:definition [ fhir:v "Sequence carries one or more amino acid substitutions relative to a natural or parent protein. Examples: insulin analogs lispro, aspart, glargine." ]
  ] [
     fhir:code [ fhir:v "truncated" ] ;
     fhir:display [ fhir:v "Truncated" ] ;
     fhir:definition [ fhir:v "Sequence is shortened relative to the parent protein." ]
  ] [
     fhir:code [ fhir:v "biotinylated" ] ;
     fhir:display [ fhir:v "Biotinylated" ] ;
     fhir:definition [ fhir:v "Covalently labelled with biotin. Typical for research or diagnostic reagents." ]
  ] [
     fhir:code [ fhir:v "fluorescent-labeled" ] ;
     fhir:display [ fhir:v "Fluorescent labelled" ] ;
     fhir:definition [ fhir:v "Covalently labelled with a fluorescent dye. Typical for imaging or flow-cytometry reagents." ]
  ] ) . # 

# -------------------------------------------------------------------------------------